Bristol-Myers Squibb

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Bristol-Myers Squibb 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BMY

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. 

CEO
Christopher S. Boerner
CEOChristopher S. Boerner
Employees
34,100
Employees34,100
Headquarters
Princeton, New Jersey
HeadquartersPrinceton, New Jersey
Founded
1933
Founded1933
Employees
34,100
Employees34,100

BMY Key Statistics

Market cap
95.08B
Market cap95.08B
Price-Earnings ratio
15.77
Price-Earnings ratio15.77
Dividend yield
5.31%
Dividend yield5.31%
Average volume
18.79M
Average volume18.79M
High today
$46.99
High today$46.99
Low today
$46.32
Low today$46.32
Open price
$46.76
Open price$46.76
Volume
9.01M
Volume9.01M
52 Week high
$63.33
52 Week high$63.33
52 Week low
$42.52
52 Week low$42.52

Stock Snapshot

As of today, Bristol-Myers Squibb(BMY) shares are valued at $46.71. The company's market cap stands at 95.08B, with a P/E ratio of 15.77 and a dividend yield of 5.3%.

As of 2025-11-09, Bristol-Myers Squibb(BMY) stock has fluctuated between $46.32 and $46.99. The current price stands at $46.71, placing the stock +0.8% above today's low and -0.6% off the high.

The Bristol-Myers Squibb(BMY)'s current trading volume is 9.01M, compared to an average daily volume of 18.79M.

During the past year, Bristol-Myers Squibb(BMY) stock moved between $42.52 at its lowest and $63.33 at its peak.

During the past year, Bristol-Myers Squibb(BMY) stock moved between $42.52 at its lowest and $63.33 at its peak.

BMY News

Nasdaq 2d
Validea Detailed Fundamental Analysis - BMY

Below is Validea's guru fundamental report for BRISTOL-MYERS SQUIBB CO (BMY). Of the 22 guru strategies we follow, BMY rates highest using our Low PE Investor m...

Validea Detailed Fundamental Analysis - BMY
Simply Wall St 3d
Bristol-Myers Squibb Is Up 9.1% After Earnings Beat and Pipeline Progress Has the Bull Case Changed?

In early November 2025, Bristol-Myers Squibb reported quarterly earnings that surpassed analyst expectations and raised its revenue guidance for the year, while...

Bristol-Myers Squibb Is Up 9.1% After Earnings Beat and Pipeline Progress Has the Bull Case Changed?
Simply Wall St 5d
Bristol-Myers Squibb’s Valuation After Strong Q3 Results and Upgraded Revenue Guidance

Shares of Bristol-Myers Squibb jumped 4% after the company reported third-quarter results that topped forecasts. The company increased its full-year revenue gui...

Bristol-Myers Squibb’s Valuation After Strong Q3 Results and Upgraded Revenue Guidance

Analyst ratings

69%

of 29 ratings
Buy
27.6%
Hold
69%
Sell
3.4%

More BMY News

TipRanks 6d
Balanced Outlook on Bristol-Myers Squibb: Strong Q3 Performance Amid ADEPT-2 Trial Concerns

Courtney Breen, an analyst from Bernstein, maintained the Hold rating on Bristol-Myers Squibb. The associated price target remains the same with $58.00. Elevate...

TipRanks 6d
Bristol-Myers Squibb Launches $7 Billion Tender Offer

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to...

People also own

Based on the portfolios of people who own BMY. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.